Person: SEVİNİR, BETÜL BERRİN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SEVİNİR
First Name
BETÜL BERRİN
Name
22 results
Search Results
Now showing 1 - 10 of 22
Publication Pedmark® reduced the risk of cisplatin-induced ototoxicity in pediatric patients with hepatoblastoma, seen in a Turkish compassionate use treatment protocol(Wiley, 2023-11-01) Cabi, Emel Ünal; Tacyıldız, Nurdan; Ataseven, Eda; Sivrice, Ayşe Çiğdem; Sevinir, Betül; Brock, Penelope; Bhattacharya, Ananya; Morgan, Allison; Baskin-Bey, Edwina; Altınel, Serdar; SEVİNİR, BETÜL BERRİN; Tıp Fakültesi; Pediatri Ana Bilim Dalı; JXF-4694-2024Publication T-cell/histiocyte-rich large B-cell lymphoma in a patient with a novel frameshift MSH6 mutation(Wiley, 2022-09-24) Çekiç, Şükrü; Aydın, Firdevs; Karalı, Yasin; Sevinir, Betül Berrin; Canöz, Özlem; Boztuğ, Kaan; Ünal, Ekrem; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; SEVİNİR, BETÜL BERRİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; Pediatrik İmmünoloji Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0002-3232-7652; 0000-0002-2691-4826; 0000-0001-8571-2581; ISC-9139-2023; L-1933-2017; AAH-1658-2021; AAH-1570-2021Publication Evaluation of micafungin use in children(Ankara Microbiology, 2020-01-01) Hacimustafaoglu, Mustafa; Yeşil, Edanur; YEŞİL, EDANUR; Çelebi, Solmaz; ÇELEBİ, SOLMAZ; Sezgin Evim, Melike; SEZGİN EVİM, MELİKE; Özer, Arife; Turan, Cansu; TURAN, CANSU; Timur, Demet; TİMUR, DEMET; Çakır, Salih Cağrı; ÇAKIR, SALİH ÇAĞRI; Bülbül, Beyhan; BÜLBÜL, BEYHAN; Ener, Beyza; ENER, BEYZA; Güneş, Adalet Meral; MERAL GÜNEŞ, ADALET; Koksal, Nilgun; Özkan, Hilal; ÖZKAN, HİLAL; Sevinir, Betul; SEVİNİR, BETÜL BERRİN; Düzcan Kilimci, Duygu; Tıp Fakültesi; Pediatri Onkoloji Ana Bilim Dalı; 0000-0002-8926-9959; 0000-0003-3146-6391; 0000-0001-5761-4757; 0000-0002-5720-1212; 0000-0002-3232-7652; 0000-0003-4646-660X; AAG-8523-2021; AEZ-2469-2022; GSO-3630-2022; AAH-1570-2021; HJZ-4508-2023; AAE-6201-2021; AAG-8393-2021; JCD-9679-2023Micafungin is recommended especially in patients with liver and kidney failure and in the presence of other side effects due to antifungals apart from its known priority indications such as invasive candidiasis. The aim of this study was to evaluate the children who have received micafungin treatment. In the study, 125 children who were hospitalized in the pediatric wards and intensive care units of our hospital and had used micafungin between November 2016 and January 2019 were analyzed retrospectively. Clinical data, micafungin indication, blood values on the first and fourth days of the treatment, side effects of the drug and efficacy were evaluated. Sixty percent (75/125) of the patients were male and the mean age of all the patients were 58 +/- 67 (0-215, 30) months. Approximately half of the cases (48%) had malignancy and 13% of them were premature. Sixty-two percent (n= 37) of the malignencies were hematological (27 acute lymphocytic leukemia, nine acute myeloid leukemia, one myelodysplastic syndrome) and 38% (n= 23) were oncological (six neuroblastoma, four Hodgkin lymphoma, two Non-Hodgkin's lymphoma, five sarcomas, one hepatoblastoma, five others) malignencies. The major cause of hospitalization was sepsis (53%). The patients had several risk factors like immunosuppressive therapy (n= 68, 54%), neutropenia (n= 61, 49%), central venous catheter (n= 102, 82%), nasogastric tube (n= 63, 50%), endotracheal intubation tube (n= 49, 39%), urinary catheter (n= 14, 11%) and total parenteral nutrition (n= 81, 65%). Thirteen percent (n= 16) of the cases were post-operative patients. Candida species were cultivated in 97 clinical specimens (blood, endotracheal aspirate, sputum, urine, etc.) among 23 (18%) of the patients. Thirteen (10%) of the patients had candidemia and 62% of them were non-albicans strains. In all candidemias, strains were echinocandin susceptible, and blood cultures were negative within four days. When all the patients (n= 125) were evaluated, a significant decrease in C-reactive protein, an increase in sodium, and a decrease in alanine aminotransferase were observed on the fourth day of micafungin treatment (p< 0.05). A total of 39 (31%) patients underwent various antifungal treatments for median seven (1-60) days prior to micafungin treatment. Fourteen (36%) of these 39 patients, had elevated liver function tests (LFT), 10 (26%) of them had hypokalemia, and five (13%) of them had elevated renal function tests. Ten (26%) patients had antifungal-induced hypokalemia previously; and potassium levels were normalized after micafungin treatment (p= 0.0001). The patients for which micafungin treatment was chosen due to elevated liver function tests (n= 47, 38%), whether the antifungalinduced or not; alanine aminotransferase and aspartate aminotransferase levels were decreased after micafungin treatment (p= 0.0001 and p= 0.0001, respectively). Nineteen (15%) of the patients have died within the first 30 days of micafungin treatment and one of them had candidemia. No micafungin treatment related significant side effects were observed in any of the patients. Our study showed that micafungin could be a safe and effective option in pediatric cases including newborns with high liver and kidney function tests.Publication Covid-19 infection in children with cancer after the first wave in Turkey: A study of the Turkish pediatric oncology (tpog) and hematology (tphd) societies(Wiley, 2021-11-01) Kebudi, R.; Kurucu, N.; Tugcu, D.; Eker, N.; Ince, D.; Tokuc, G.; Cecen, R. E.; Vural, O.; Demirdag, T.; Koc, A.; Kara, B.; Uzel, H.; Tuncel, D.; Citak, C.; Kartal, I.; Canpolat, C.; Ozguven, A.; Elli, M.; Acipayam, C.; Toret, E.; Karakas, Z.; Turkkan, E.; Kocak, U.; Tufekci, O.; Bay Buyukkapu, S.; Orhan, M.; Albayrak, C.; Albayrak, D.; Sen, H.; Bicakci, Z.; Ozbek, N.; Somer, A.; Kara, A.; Erdem, M.; Sevinir, B.; SEVİNİR, BETÜL BERRİN; Tıp Fakültesi; Pediatri Onkoloji Ana Bilim Dalı; 0000-0001-5291-2923; 0000-0001-7523-7553; 0000-0002-4811-4803; 0000-0001-8081-6760; 0000-0002-1321-4708; 0000-0002-1654-3232; AAD-8047-2020; HPG-6298-2023; I-9081-2013; AAJ-6924-2021; AAA-5354-2021; HLH-1182-2023; AAA-4820-2022; AAZ-4692-2020; O-4389-2018Publication A 3 year review of a cohort turkish paediatric oncology group (TURKPEDPGx)(Wiley, 2018-11-01) Baskın, Y.; Uncu, B.; Leblebici, A.; Kocal, G. Calibasi; Çitak, C.; Ak, E.; İnce, D.; Kızmazoğlu, D.; Sevinir, B. B.; Küpeli, B.; Avcı, M.; Oniz, H.; Çeçen, E.; Ellidokuz, H.; Olgun, N.; SEVİNİR, BETÜL BERRİN; Tıp Fakültesi; Pediatri Onkoloji Bölümü; AAH-1570-2021Publication Pediatric multilocular cystic nephroma extending into the renal pelvis and ureter(Galenos Yayıncılık, 2014-11-01) Doğan, Hasan Serkan; Yazıcı, Zeynep; Aytac, Berna; Sevinir, Betül; Erdoğan, Hakan; Çiçek, Çağatay; YAZICI, ZEYNEP; AYTAÇ VURUŞKAN, BERNA; SEVİNİR, BETÜL BERRİN; ÇİÇEK, MEHMET ÇAĞATAY; Tıp Fakültesi; Üroloji Ana Bilim Dalı; AAH-1570-2021; AAI-2303-2021; AAH-9746-2021; JLG-1312-2023Multilocular cystic nephroma (MCN) is a rare tumor at the most benign end of the spectrum of the multilocular cystic neplasms of kidney. Nephrectomy is curative for MCN. In this case-report, we present a 16-month-old girl with a 10x15 cm multilocular cystic renal tumor extending into the renal pelvis and proximal ureter on the right side demonstrated on magnetic resonance imaging. Nephrectomy was performed. The pathology was completely consistent with MCN.Publication Cancer in patients with primary immune deficiency(Wiley, 2016-11-01) Demirkaya, M.; Sevinir, B.; Kılıç, S.; Öztürk, H.; Demirkaya, Metin; SEVİNİR, BETÜL BERRİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; ÖZTÜRK NAZLIOĞLU, HÜLYA; IXQ 3375 2023; Çocuk Onkoloji Ana Bilim Dalı; 0000-0002-3232-7652; AAH-1570-2021; EUG-4353-2022; IDK-5744-2023Publication Approach to childhood mediastinal mass(Galenos Yayincilik, 2016-04-01) ; GÜLER, SALİH; Güler, Salih; Demirkaya, Metin; Sevinir, Betül; SEVİNİR, BETÜL BERRİN; 0000-0002-3232-7652; AAH-1570-2021A significant portion of the thoracic masses in childhood are seen in the mediasten. For practical identification of tumors that originate from different tissues, the mediasten is divided into two parts as superior and inferior. The inferior part is subdivided into three portions as anterior, middle and posterior. Mediastinal masses may be malignant or non-malignant. The symptoms vary according to the size and location of the mass. Anterior mediastinal masses are important because of the possibility to press the airways and great arteries. On the other hand, posterior mediastinal masses are also important because of the possibility to extend into intramedullary area and press to nerve roots. According to the symptoms and signs that occur depending on the size and pressure of the mass, immediate treatment may be required. While history and physical examination are important for diagnosis, imaging and laboratory tests are also helpful. Histopathological evaluation is often required for definitive diagnosis.Publication Central nervous system metastases in neuroblastoma: Results of turkish pediatric oncology group neuroblastoma 2009 (TPOG-NB-2009) protocol(Wiley, 2018-11-01) Çeçen, E.; İnce, D.; Sevinir, B.; Çakır, F. B.; Kurucu, N.; Güler, E.; Vural, S.; Köksal, Y.; Öniz, H.; Oğuz, A.; Sarıalıoğlu, F.; Olgun, N.; SEVİNİR, BETÜL BERRİN; Tıp Fakültesi; Pediatri Onkoloji Bölümü; AAH-1570-2021Publication Delayed chemotherapy-induced nausea and vomiting in children with cancer(Galenos Yayincilik, 2011-04-01) Demirkaya, Metin; Sevinir, Betül; SEVİNİR, BETÜL BERRİN; Demiral, Meliha; Özdemir, Ramazan; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0002-3232-7652; AAH-1570-2021Introduction: The incidence of chemotherapy-induced late emesis and vomiting in pediatric oncology patients and the related factors were investigated.Materials and Method: The study consisted of the patients aged between 0-18 years and given chemotherapy between January and December 2009. The amount of vomiting was described on numbers and the grade of nausea was described between 0-10. Vomiting and nausea was evaluated daily by the same clinician.Results: Sixty nine late nausea and vomiting episodes in 35 patients were evaluated. There were 22 females and 13 males in the study group. Mean age was 8.88 +/- 5.43 (1 to 17) years. Late nausea was found 2.8% on the first day, 81.1% on the second day, 68% on the third day, 46.3% on the fourth day and 24.6% on the fifth day. Late emesis was found 1.4% on the first day, 65.2% on the second day, 43.5% on the third day, 24.6% on the fourth day and 13% on the fifth day. There was no significant difference in nausea and emesis between boys and girls. There was a positive correlation between the age and nausea/ emesis episodes. The correlation coefficients between age and nausea grade on 2, 3, 4 and 5th days were 0.29, 0.27, 0.33, and 0.24, respectively; and p values were 0.013, 0.023, 0.005 and 0.046, respectively. The degree of the emetogenic potential of drugs on the number of emesis and the severity of nausea was found to be not significant. The vomiting was statistically significant on second and third days and grade of nausea on first, second and third days in the patients given cisplatin.Conclusion: In this study, it was found that emesis was most seen in the second day of chemotherapy, the grade of vomiting was higher in patients receiving cisplatin and there is a positive correlation between age and grade of nausea.
- «
- 1 (current)
- 2
- 3
- »